Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB – Get Free Report) have been given a consensus recommendation of “Hold” by the six analysts that are presently covering the company, Marketbeat reports. Cytek Biosciences had a negative return on equity of 10.07% and a negative net margin of 36.25%. On average, sell-side analysts forecast that Cytek Biosciences will post -0.21 EPS for the current fiscal year. Cytek Biosciences Company Profile(Get Free Report)Cytek Biosciences is a biotechnology company specializing in innovative cell analysis solutions. Featured ArticlesReceive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.